Pharsight

Drugs that contain Rivaroxaban

1. Xarelto patents expiration

XARELTO's oppositions filed in EPO
XARELTO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157456 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Aug, 2024

(5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415053 JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
Nov, 2024

(8 months from now)

US7157456

(Pediatric)

JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Feb, 2025

(11 months from now)

US9415053

(Pediatric)

JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
May, 2025

(1 year, 2 months from now)

US9539218 JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Feb, 2034

(9 years from now)

US9539218

(Pediatric)

JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Aug, 2034

(10 years from now)

US10828310 JANSSEN PHARMS Reducing the risk of cardiovascular events
Jan, 2039

(14 years from now)

US10828310

(Pediatric)

JANSSEN PHARMS Reducing the risk of cardiovascular events
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Aug 23, 2024
Pediatric Exclusivity (PED) Feb 23, 2025

Market Authorisation Date: 01 July, 2011

Treatment: Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Treatment of deep vein thrombosis (dvt); Reduction of risk of major cardiovascular events (cv death, mi, and st...

Dosage: TABLET;ORAL

How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage

XARELTO family patents

Family Patents